<DOC>
	<DOC>NCT00347425</DOC>
	<brief_summary>The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.</brief_summary>
	<brief_title>Switch Study of Existing Atypical Antipsychotics to Bifeprunox</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Males or females, 1865 years, meeting DSMIV TR diagnosis of Schizophrenia or Schizoaffective Disorder for whom a switch is indicated Acutely psychotic or with a current Axis I primary psychiatric diagnosis other than schizophrenia or schizoaffective disorder based on DSMIV TR criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Switch Study</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Atypical Antipsychotics</keyword>
</DOC>